Discontinuation of Treatment
The usage of biological agents is updated in Table 2 . Twenty-seven percent of the treatment courses involved etanercept, which remained the commonest biological agent ever used. Etanercept was also the most frequent agent that was currently used by patients (26.9%). Figures  1-3 show the ever and current use of the biologic and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis.
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Demographic Data
Up to November 2017, a total of 4216 courses of biologics were used in 2616 patients (1517 women and 1099 men) with various rheumatic diseases in our Registry. The mean age at the commencement of treatment was 46.9 years (range 1-89 years). More than half of the patients suffered from rheumatoid arthritis, while the others were mainly patients with ankylosing spondylitis and psoriatic arthritis. Other indications of the biological agents are shown in Table 1 . The longest duration of therapy was 168 months.
Co-morbid Conditions
The most common co-existing medical conditions of patients who were treated with the biological agents were hypertension (18.5%), diabetes mellitus (7.1%), depression (4.4%), fatty liver (4.4%), peptic ulcer (4.3%) and chronic hepatitis B infection (4.0%). Other co-morbid conditions reported were previous pulmonary tuberculosis (3.8%), asthma (2.5%), liver disease (2.4%), renal disease (2.3%), ischemic heart disease (2.1%), hyperthyroidism (1.9%), cancer (1.7%), stroke (1.1%), congestive heart failure (0.6%), heart attack (0.6%), epilepsy (0.6%), previous extra-pulmonary tuberculosis (0.5%), COAD (0.5%), chronic hepatitis C infection (0.3%) and demyelination (0.04%).
The number of patients who withdrew from treatment at different time points is shown in Table 3 . The three most commonly reported reasons for the termination of treatment are lack of efficacy (43%), serious adverse effects (23%) and cost (11%). Other reasons for stopping the treatment included marked improvement in disease activity (9%), end of research study (7%) and patients' preference (3%).
Major Adverse Events Reported

Neoplasia
There were 43 cases of malignant and pre-malignant conditions reported: colon cancer (N=4), lung cancer (N=4), rectum cancer (N=4), breast cancer (N=3), ovarian cancer (N=3), tongue cancer (N=1), caecum cancer (N=1), intraductal papillary mucinous neoplasm of pancreas (N=1), prostate cancer (N=1), stomach cancer (N=1), penile cancer (N=1), gall bladder cancer (N=1), cancer of urinary bladder (N=1), cancer of small intestine (N=1), kidney cancer (N=1), cancer of ampulla of vater (N=1), thyroid cancer (N=1), mandible cancer (N=1), adenocarcinoma (N=1), myeloma (N=1), cervical intra-epithelial neoplasia (CIN) (N=1), myelodysplastic syndrome (N=1), brain tumor (N=1), malignant melanoma (N=1), renal cell carcinoma (N=1), lymphoma (N=1), nasopharyngeal cancer (N=1), cancer of nasal cavity (N=1), cervical cancer (N=1) and myeloproliferative neoplasms (N=1).
Infection Requiring Hospitalization
There were 134 episodes of infective complications requiring hospitalization. Around 61% of them (i.e., 82 cases) occurred during the first 12 months of biological therapy.
Tuberculosis
A total of 60 cases of TB were reported: 31 related to Infliximab, 12 related to Etanercept, 9 related to Adalimumab, 4 related to Golimumab, 3 related to Tocilizumab and 1 related to Tofacitinib. Nearly 40% of the cases (i.e., 23 cases) occurred in the first 6 months of treatment. There were 482 abnormal CXRs before the treatment and isoniazid chemoprophylaxis was given to 835 patients (32%) with latent TB, as defined by either positive MT2 (≥ 10mm induration) or a positive Interferon gamma release assay (IGRA) test. 
Reasons for withdrawal
